Novartis to Acquire Excellergy for Up to $2 Billion to Enhance Food Allergy Drug Offerings

Pharmaceutical giant Novartis has declared its plan to acquire the biotech company Excellergy in a deal valued at up to $2 billion, representing its second significant acquisition within a fortnight.

The Swiss-based drug manufacturer revealed that the agreement entails both upfront and incremental payments that could total $2 billion. The transaction is anticipated to finalize in the latter half of 2026, pending standard conditions such as regulatory approvals.

Through this acquisition, Novartis aims to bolster its position in the immunology sector, particularly within the food allergy treatment arena. Excellergy’s leading drug candidate, Exl-111, is formulated to offer prompt relief from allergy symptoms, positioning it as a valuable addition to Novartis’ growing portfolio.

This deal is in line with another substantial agreement by Novartis last week, involving the acquisition of a breast cancer drug candidate from US firm Synnovation Therapeutics for up to $3 billion, highlighting a broader strategy to enhance its offerings through strategic acquisitions.

In addition to acquisitions, Novartis has been increasing its investment endeavors in the United States. Last April, the company announced a plan to invest $23 billion over five years for the construction and expansion of research, development, and manufacturing facilities nationwide.